5-fluorouracil + cetuximab

5-fluorouracil + cetuximab is a combination regimen used primarily in the treatment of certain cancers, most notably recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) and metastatic colorectal cancer. 5-fluorouracil (5-FU) is a small molecule antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death. Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream signaling pathways involved in tumor cell proliferation, survival, angiogenesis, invasion, and metastasis. The combination leverages both cytotoxic chemotherapy (from 5-FU) and targeted therapy (from cetuximab), resulting in improved efficacy compared to chemotherapy alone for certain indications[1][2][4][6].

Other names

5-FU + cetuximabfluorouracil + cetuximab